Biomarker Study for Churg-Strauss Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial focuses on eosinophilic granulomatosis with polyangiitis (EGPA), a rare disorder affecting the immune system. EGPA can lead to asthma, elevated levels of certain white blood cells, and inflammation of blood vessels. The trial aims to identify new biological markers to assess disease severity over time. Individuals diagnosed with EGPA may be suitable for this longitudinal study, which is conducted over an extended period. As a Phase 2 trial, the research measures the treatment's effectiveness in an initial, smaller group, providing participants an opportunity to contribute to significant advancements in EGPA treatment.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
Why are researchers excited about this trial?
Researchers are excited about this longitudinal study for Eosinophilic Granulomatosis With Polyangiitis (EGPA) because it focuses on understanding the long-term progression and outcomes of the condition. Unlike standard treatments like corticosteroids and immunosuppressants, which primarily manage symptoms, this study aims to gather comprehensive data over time to uncover patterns and potential new therapeutic targets. By tracking the disease's progression, researchers hope to identify factors that influence patient outcomes and develop more personalized and effective treatment strategies in the future.
Who Is on the Research Team?
Peter A. Merkel, MD, MPH
Principal Investigator
University of Pennsylvania
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Longitudinal Study
Participants undergo study visits every 6 months or annually for biomarker assessment and disease activity monitoring
Follow-up
Participants are monitored for safety and effectiveness after the main study period
What Are the Treatments Tested in This Trial?
Interventions
- Longitudinal Study
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pennsylvania
Lead Sponsor
AstraZeneca
Industry Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
GlaxoSmithKline
Industry Sponsor
Dame Emma Walmsley
GlaxoSmithKline
Chief Executive Officer since 2017
MA in Classics and Modern Languages from Oxford University
Dr. Hal Barron
GlaxoSmithKline
Chief Medical Officer since 2018
MD from Harvard Medical School
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.